Kathrine Lederballe Grøn

Author

Also Known As

Gron, Kathrine Lederballe, Grøn, Kathrine L., K. GRON, K. Grön, K. Grøn, K. Lederballe Gron, K.L. Grøn, Kathrine Grøn, Kathrine L Grøn, Kathrine L. Grøn

Publications

715

Citations

H-Index

Concepts

All Affiliations

University of Copenhagen Rigshospitalet Glostrup Hospital Aarhus University Hospital Karolinska Institutet

About

Kathrine Lederballe Grøn is an author at University of Copenhagen.

Kathrine Lederballe Grøn

Publications

685

Citations

H-Index

Page 1

	Year	Citations
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft, Annals of the Rheumatic Diseases	2017	245
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, BMJ	2020	108
The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Kathrine Lederballe Grøn, Lykke Midtbøll Ørnbjerg, Merete Lund Hetland, PubMed	2015	74
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden Kathrine Lederballe Grøn, Elizabeth V. Arkema, Bente Glintborg, Annals of the Rheumatic Diseases	2019	65
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial Mikkel Østergaard, Ronald van Vollenhoven, Anna Rudin, Annals of the Rheumatic Diseases	2023	44
Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study Kathrine Lederballe Grøn, Bente Glintborg, Mette Nørgaard, Lara D. Veeken	2019	39
Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model Simon Krabbe, Kathrine Lederballe Grøn, Bente Glintborg, Lara D. Veeken	2021	27
<scp>One‐Year</scp> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses Bente Glintborg, Ulf Lindström, Daniela Di Giuseppe, Arthritis Care & Research	2020	26
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis Ulf Lindström, Bente Glintborg, Daniela Di Giuseppe, Lara D. Veeken	2020	25
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries Bénédicte Delcoigne, Lotta Ljung, Sella Aarrestad Provan, Annals of the Rheumatic Diseases	2022	17

Page 1